Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

about

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Cardiotoxicity of Anticancer Therapeutics.

P2860

Q49315568-3362A556-7A6D-4827-8DC3-1B86B6D4286D Q50326869-782BE154-1057-44D3-8319-246F10B62F70

P2860

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Item

http://www.wikidata.org/entity/Q39186183

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@en

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@nl

type

Item

label

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@en

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@nl

prefLabel

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@en

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@nl

P1476

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

@en

P2093

Michael G Fradley

http://www.w3.org/2001/XMLSchema#string

Rongras Damrongwatanasuk

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of the Philadelphia chromosome: a personal perspective

Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension

The biology of VEGF and its receptors

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

P2888

s11936-017-0524-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11936-017-0524-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28316033

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

about

P2860

P2860

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921